Are the currently recommended doses of benzathine penicillin G adequate for secondary prophylaxis of rheumatic fever?
- PMID: 8637788
Are the currently recommended doses of benzathine penicillin G adequate for secondary prophylaxis of rheumatic fever?
Abstract
Objective: To review the literature on dose and regimens of intramuscular benzathine penicillin G (BPG) for secondary prophylaxis of recurrent rheumatic fever.
Setting: For over 40 years BPG has been the gold standard for secondary prophylaxis, usually as a dose of 1,200,000 U (900 mg). Although studies have suggested that BPG injections every 3 weeks are superior to injections every 4 weeks, implementation of an every 3 weeks regimen can be problematic with regards to both patient compliance (adherence) and an increased burden on health resources.
Findings: Some of the earliest studies of BPG suggested that larger doses resulted in prolongation of detectable penicillin levels. A recent study assessing plasma penicillin levels after BPG doses of 1,200,000 U, 1,800,000 U, and 2,400,000 U suggested there may be benefits in a BPG regimen every 4 weeks with doses higher than the standard 1,200,000 U.
Conclusions: Further studies of higher dose BPG regimens seem justified. In addition, further work is needed on quality and storage options for different BPG preparations; location and method of BPG injections; the importance of weight differences between individuals; and ways of improving access to and compliance with BPG regimens.
Similar articles
-
Rheumatic fever prophylaxis using benzathine penicillin G (BPG): two- week versus four-week regimens: comparison of two brands of BPG.Pediatrics. 1996 Jun;97(6 Pt 2):992-5. Pediatrics. 1996. PMID: 8637789 Clinical Trial.
-
A case of rheumatic fever with multiple recurrences of carditis.Turk J Pediatr. 2008 Mar-Apr;50(2):186-8. Turk J Pediatr. 2008. PMID: 18664087
-
Penicillin Dried Blood Spot Assay for Use in Patients Receiving Intramuscular Benzathine Penicillin G and Other Penicillin Preparations To Prevent Rheumatic Fever.Antimicrob Agents Chemother. 2017 Jul 25;61(8):e00252-17. doi: 10.1128/AAC.00252-17. Print 2017 Aug. Antimicrob Agents Chemother. 2017. PMID: 28559267 Free PMC article.
-
Severe adverse reactions to benzathine penicillin G in rheumatic heart disease: A systematic review and meta-analysis.PLoS One. 2025 May 7;20(5):e0322873. doi: 10.1371/journal.pone.0322873. eCollection 2025. PLoS One. 2025. PMID: 40333929 Free PMC article.
-
Acute rheumatic fever.BMJ. 2015 Jul 14;351:h3443. doi: 10.1136/bmj.h3443. BMJ. 2015. PMID: 26175053 Review. No abstract available.
Cited by
-
Prevention and treatment of rheumatic heart disease in the developing world.Nat Rev Cardiol. 2009 Nov;6(11):689-98. doi: 10.1038/nrcardio.2009.162. Epub 2009 Sep 15. Nat Rev Cardiol. 2009. PMID: 19752868 Review.
-
A population pharmacokinetic modeling approach shows that serum penicillin G concentrations are below inhibitory concentrations by two weeks after benzathine penicillin G injection in the majority of young adults.Antimicrob Agents Chemother. 2014 Nov;58(11):6735-41. doi: 10.1128/AAC.02744-14. Epub 2014 Sep 2. Antimicrob Agents Chemother. 2014. PMID: 25182635 Free PMC article.
-
No demonstrable effect of benzathine penicillin on recurrence of rheumatic Fever in pacific island population.Pediatr Cardiol. 2010 Aug;31(6):849-52. doi: 10.1007/s00246-010-9718-5. Epub 2010 Apr 22. Pediatr Cardiol. 2010. PMID: 20411251
-
Rheumatic heart disease in Africa: is there a role for genetic studies?Cardiovasc J Afr. 2015 Mar-Apr;26(2 Suppl 1):S21-6. doi: 10.5830/CVJA-2015-037. Cardiovasc J Afr. 2015. PMID: 25962944 Free PMC article. Review.
-
Rheumatic Fever.Curr Treat Options Cardiovasc Med. 1999 Oct;1(3):253-258. doi: 10.1007/s11936-999-0041-5. Curr Treat Options Cardiovasc Med. 1999. PMID: 11096490
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical